Michael Winter, MD
Gastroenterology · Lebanon, NHNPI 1003172180
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (56.0%), education and consulting fees — rather than concentrated in one kind of arrangement. Pfizer accounts for 86.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $50,408 and has fallen 92.7% since, to $3,679 in 2025. Among gastroenterology clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $2139.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$50K
- Celltrion USA Inc.$4K
- AbbVie$4K
- E.r. Squibb & Sons, L.L.C.$362
- Bristol Myers Squibb$55
- Takeda Pharmaceuticals U.S.A., Inc.$53
- plus $84 from 4 others
What the payments were for
- Consulting fees$6,56211%
- Grants$32,31656%
- Travel & lodging$6941%
- Food & beverage$4921%
- Education$17,69131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 2 | $50,000 |
| Celltrion USA Inc. | 4 | $3,679 |
| AbbVie | 10 | $3,523 |
| E.r. Squibb & Sons, L.L.C. | 1 | $362 |
| Bristol Myers Squibb | 1 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Acell, Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $15 |
| Dynavax Technologies Corporation | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,755 in reported general payments places this provider in the 90th percentile of 91 gastroenterology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 18 | $441,675 |
| Humira(Cf) PenAdalimumab | 12 | $104,877 |
| Mesalamine | 33 | $12,851 |
| CholestyramineCholestyramine (With Sugar) | 49 | $3,098 |
| LoperamideLoperamide Hcl | 13 | $550 |
| Omeprazole | 34 | $316 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Lebanon
- Lee KaplanLebanon$1.2M
- Corey SiegelLebanon$602K
- Brian LacyLebanon$177K
- Shelby SullivanLebanon$137K
- Stuart GordonLebanon$42K
- Timothy GardnerLebanon$17K
- Liam ZakkoLebanon$5K
- Michael CurleyLebanon$4K
- Nicholas HannonLebanon$3K
- Leon McLeanDerry$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.